But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
Regulators are focusing on the Food and Drug Administration’s Orange Book, which compiles approved drugs along with patent listings. Altogether, the FTC sent letters to 10 companies, alleging ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk ... on," FTC Chair Lina Khan said. The agency sent letters to 10 companies, warning that their patent listings were ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining ... they rely on,” FTC Chair Lina Khan ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
And they don't really have the inside view of what's happening at the FDA.” Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, ...
the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications. To date, the FTC’s Orange Book patent disputes have been ...
But other companies argue that the FTC’s accusation that their patents are junk isn’t accurate. Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to ...
But now, the FTC says drugmakers are gaming the system by filing what it described as “junk patents”. Those are patents that don’t really protect intellectual property or the innovation in h ...